Phytotherapy Research Pharmacology
Alginic Acid Ameliorates Osteoarthritis Through <scp>FOXO3a</scp> ‐Dependent Regulation of the <scp>EREG</scp> – <scp>MAPK</scp> Signaling Axis
Abstract
ABSTRACT Osteoarthritis (OA) lacks effective disease‐modifying therapies. This study evaluated the therapeutic potential of alginic acid (AA), which was identified through a FOXO3a‐oriented virtual screening strategy, and investigated its downstream regulatory mechanism with a focus on the EREG–MAPK signaling axis. AA was prioritized through structure‐based virtual screening against FOXO3a followed by functional secondary screening. In vitro, IL‐1β‐stimulated human OA chondrocytes were treated with AA and assessed for extracellular matrix metabolism, inflammation, apoptosis, and MAPK pathway activity. FOXO3a knockdown and EREG‐overexpression rescue experiments were performed to evaluate the functional roles of FOXO3a and EREG. In vivo, DMM‐induced OA rats received intra‐articular AA treatment, followed by assessment of pain behavior, cartilage pathology, and matrix preservation. Transcriptomic analysis was used to identify AA‐responsive genes and signaling pathways under OA‐like inflammatory conditions. AA promoted cartilage matrix synthesis, reduced matrix degradation and inflammatory responses, and attenuated chondrocyte apoptosis in vitro. In DMM‐induced OA rats, AA alleviated pain hypersensitivity and reduced cartilage degeneration. Transcriptomic and subsequent validation analyses identified EREG and MAPK signaling as AA‐responsive components. AA reduced EREG expression and MAPK phosphorylation. Importantly, FOXO3a knockdown markedly attenuated the effects of AA on EREG expression, p38 MAPK activation, and cartilage matrix homeostasis, supporting a functional requirement for FOXO3a in AA‐mediated chondroprotection. Conversely, EREG overexpression partially counteracted the protective effects of AA. AA exerts chondroprotective effects in experimental OA and appears to act, at least in part, through FOXO3a‐dependent suppression of EREG–MAPK signaling. These findings strengthen the mechanistic basis for AA as a potential OA therapeutic candidate while supporting further investigation of the FOXO3a–EREG–MAPK regulatory axis.